Company intelligence / Profile preview
Mustang Bio
Waltham, Massachusetts, United Statesorpha.net ↗
- Ownership
- Public · MBIO
- Employees
- ~6
- Development stage
- Phase 1
01
Overview
Mustang Bio’s lead program, MB‑106, a CD20-targeted autologous CAR T-cell therapy for B-cell NHL and CLL, has shown a favorable safety and efficacy profile. In Waldenstrom macroglobulinemia patients from the Phase 1/2 trial cohort, an overall response rate of 90% was observed with durable responses—one patient remains in complete remission at 31 months. Outpatient administration was feasible. There are currently no FDA-approved CAR-T treatments for WM[10]. The company also develops gene therapies for rare diseases such as X-SCID.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- CAR-T cell therapies (chimeric antigen receptor T cells)Gene therapies (lentiviral-based)Oncolytic virus therapy
- Industry
- Biotech
02
Drug pipeline
27 assets26 more assets in the full pipeline.
Request access →03
Partnerships
– Fred Hutchinson Cancer Center (“Fred Hutch”) – development of MB–106 and other CAR–T programs[6][8].– City of Hope National Medical Center – glioblastoma and AML programs.– St Jude Children’s Research Hospital – licensing of X–SCID gene therapy.– Nationwide Children’s Hospital — oncolytic virus program.– CSL Behring — Cytegrity stable producer line license agreement[2].– uBriGene Biosciences — manufacturing partnership[9].
04
Financials
- Market cap
- $4M
- Total revenue
- $0
- Enterprise value
- $-11.1M
Beyond the preview
Go deeper on Mustang Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mustang Bio.